To better understand the FDA-issued guidelines on incorporating patient-reported outcome measures (PROMs), we've compiled a white paper, sharing key insights on recent developments and crucial considerations for an effective Clinical Outcome Assessment (COA) strategy.
See how we helped an emerging biopharma company accelerate phase 1 of a new treatment for relapsed/refractory multiple myeloma, enabling successful application for breakthrough therapy designation.
If you missed Signant’s webinar about optimizing patient-reported outcomes measurement strategy throughout oncology drug development, we’ve summarized the key takeaways and provided the recording.
Leverage our unparalleled blend of cutting-edge technology, scientific expertise, worldwide reach, and seasoned services to employ proficiency in eCOA, RTSM, and eConsent solutions, across every stage of oncology clinical drug development.
